Impact of Chemotherapy and Anticancer Agent Type on 30-Day All-Cause In-Hospital Mortality of Venous Thromboembolism Patients With Cancer in Japan
In this study, 30-day mortality was lower in the group with than without chemotherapy group. Among VTE patients with cancer, direct Factor Xa inhibitors appear to be preferred over warfarin due to bleeding risk.
Authors
- Mari Kogo (ORCID: https://orcid.org/0000-0001-7553-0872)
- Takahiro Okada (ORCID: https://orcid.org/0000-0001-6375-2443)
- Mio Ebato (ORCID: https://orcid.org/0000-0001-8594-1552)
- Tsutomu Toshida
- Hiroshi Suzuki (ORCID: https://orcid.org/0000-0002-8698-7357)
- Yoshitaka Iso (ORCID: https://orcid.org/0000-0002-4687-0453)
- Shuichi Nawata (ORCID: https://orcid.org/0000-0002-2193-9899)
- Tomiko Sunaga (ORCID: https://orcid.org/0000-0002-1316-5192)
Institutions
- SHOWA Medical University (JP)
- Hoshi University (JP)
- SHOWA Medical University Northern Yokohama Hospital (JP)
- SHOWA Medical University Fujigaoka Hospital (JP)
- SHOWA Medical University Hospital (JP)
Publication Details
- Journal
- Circulation Reports
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1253/circrep.cr-25-0170
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Kowa Company
- Toa Eiyo
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Japan Society for the Promotion of Science
- Daiichi Sankyo Europe